logo
Incontinence stopped Olympian Krishna Stanton in her tracks, but then she found a way forward

Incontinence stopped Olympian Krishna Stanton in her tracks, but then she found a way forward

Faecal incontinence can be tricky to talk about. It can get awkward and uncomfortable. So naturally, it isn't a subject that comes up much.
It's an issue however, that affects over 400,000 Australian women.
One of those women is former Olympian, Commonwealth Games silver medallist and World Record holder, distance runner Krishna Stanton.
Running was her life. And then she had to stop.
"I don't think I really spoke to anyone about it, about how distressing it was," Stanton said.
"I would say [it was] isolating."
Colorectal surgeon Dr Andrea Warwick has been working in the field for over 20 years.
She says for people who experience incontinence, sport can be one of the first things to go.
"People stop doing things, running is often particularly problematic," she said.
"And their symptoms really affect everything in the rest of their life as well."
Source: Continence Foundation of Australia
Incontinence is the involuntary loss of bladder or bowel control. There's a large spectrum of how it can present.
At first, it could be rushing to the toilet.
"That urgency to get to the toilet can hugely affect people's lives," Dr Warwick said.
"They don't leave the house, they don't go to work, they lose social activities."
And then there's what Dr Warwick calls the full-blown kind.
"That can go from a small amount of leaking on your undies up to liquid stool running down people's legs."
She says it's common for people to wait until things get really bad before they seek help.
"They adapt their lifestyle to try and stop it from [making an] impact."
The Continence Foundation of Australia's latest report indicates 27 per cent of Australians have incontinence.
The age group with the largest number of sufferers, is actually 40 - 44 year olds.
It takes quite a toll, with 40 per cent of people with incontinence saying it affects their mental health and wellbeing — 10 per cent even avoid going out because of it.
It's mainly women who experience both or either forms (urinary and faecal), and is common in those who have carried a baby or had birth injuries.
There's also a significant number who suffer after menopause.
"A lady may have had an injury to their pelvic floor during childbirth which hasn't previously caused them problems, but after menopause and as they get older and muscles generally weaken, they start developing problematic symptoms," Dr Warwick said.
For Stanton, it was a bit more complex.
Stanton is the epitome of resilience. Her running career was full of ups and downs.
In 1987 she came fourth at the World Indoor Championships, but later that year broke a bone in her foot. It took two operations and two years to heal.
In 1990 she won the Australian Championships over 3,000-metres, then made the 1992 Barcelona Olympics. Five days out from her race, she got bitten by a spider on the foot. She competed but finished in a time well below her best.
In 1996 Stanton delivered her son Zachary in a breech birth, which led to urinary incontinence.
Do you have a story idea about women in sport?
Email us abcsport5050@your.abc.net.au
"There was a 12-centimetre internal tear, so I was unable to run because I just couldn't control my bladder," she said.
After working with physiotherapists, she won the 2001 Sydney Marathon and qualified for the 2002 Commonwealth Games.
It was here she got a silver medal, and a great feeling of satisfaction.
"To be able to come back from those [health issues] and win a silver medal was really worthwhile," Stanton said.
Her next goal was to qualify for the 2006 Commonwealth Games before retiring. But a catalyst the year before put that dream to bed.
"In 2005 I got food poisoning, which triggered my body to basically shut down," Stanton said.
It led to constant diarrhoea.
"I just never knew when I needed to go to the bathroom," Stanton said.
"You could never relax, it's constant stress."
Stanton wasn't sure what was happening to her body but stayed focused on her goals.
"I was losing so much weight, not knowing what was wrong, still trying to run," she said.
"Then there's a 12-centimetre tear still there from [Zachary's] birth. Me trying to run was putting pressure on everything."
Stanton suffered a bowel prolapse, which was operated on multiple times.
A gastroenterologist then diagnosed her with Coeliac disease which she was told she'd had for many years.
Stanton said the nerves in her bowel were all but destroyed.
"I always had this philosophy, and it's probably come from my running, that there's always someone worse off," she said.
"It was just something I thought I had to deal with. It was frustrating, upsetting, but it was just my lot."
Stanton spent years adapting to her incontinence.
If she went for a walk, it would be in a park with bathrooms. She didn't do buses or trains and found car trips and plane rides stressful.
And of course, running was off the cards.
"Obviously there were times when I was just in tears," Stanton said.
Her doctor eventually advised her to see a surgeon, and it was only after that that life got back to normal.
Dr Warwick says there's a host of different treatments for incontinence, ranging from lifestyle changes to surgery.
"Oftentimes we start with basic treatments of managing people's diet, stool consistency [and] physiotherapy," she said.
"And a lot of people will get better with those interventions."
Stanton's case was more extreme. Her doctor recommended sacral neuromodulation, which involves surgery.
It's where a device with wires attached to a pacemaker is inserted under the skin in the buttock. It directly stimulates a nerve with an electrical current to alter or improve bladder or bowel function.
Dr Warwick says it can change someone's life dramatically, and Stanton agrees.
"I feel blessed," Stanton said.
"It took a while to manage, but it's restored those nerves so that I can now run.
"I've had some surgeries to help that as well, but I would say it's really changed what I thought in that time my life was going to be."
Stanton set a goal of doing a run for her 50th birthday in 2016. In true form, she achieved it.
She ran the Gold Coast Marathon as a tribute to her late teammates Kerryn McCann and Jackie Fairweather, who she stood on the podium with at the 2002 Commonwealth Games.
Fairweather took her own life in 2014, and McCann died from breast cancer in 2008.
"So, I thought what I'd been through wasn't that much," Stanton said.
"And so, if I could run, I would."
In 2022 Stanton ran the London Marathon in world record time for her age group.
The record was broken six months later, and she's on a mission to break it back at this year's Sydney Marathon in August.
The way Stanton's faecal incontinence came about is not common, but her sentiment of it taking control of her life is.
She's speaking out now to help others who might be suffering.
"I would like people to know that there's an option, and it can make a real difference," Stanton said.
Dr Warwick says she doesn't want to see people give up sport, that there are ways to keep on playing.
"Oftentimes people come to me 20 years after they've been struggling with symptoms," she said.
"They say I wish I'd done this earlier. I wish I hadn't compromised my life for something that can be treated.
"I guess that's the biggest thing I'd say. You don't have to suffer with these problems."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Port Adelaide star Ollie Wines considering second surgery to address heart irregularity
Port Adelaide star Ollie Wines considering second surgery to address heart irregularity

ABC News

time25 minutes ago

  • ABC News

Port Adelaide star Ollie Wines considering second surgery to address heart irregularity

Port Adelaide's Brownlow medallist Ollie Wines is considering more heart surgery at the end of the AFL season. Wines suffers from a heart irregularity which sometimes causes palpitations, leading him to be substituted out of three games in the past four seasons. The 30-year-old admits frustration at the condition arising most recently — and forcing his substitution — from Port's away win against Sydney on April 20. That episode followed heart surgery last December in a bid to correct the issue. "I had a procedure back in December and there was 1 per cent likeliness that it wouldn't work," Wines told reporters on Monday. "And unfortunately, I'm in the 1 per cent that it hasn't worked. "So we've gone back to a bit of an intervention plan that we had the previous two years to manage it up to that operation and that is working well so far. "We will reassess at the end of the season to see if we do it again and try a surgical operation." But Wines remained pragmatic about his heart issue. "It was frustrating (to be subbed out against Sydney)," he said. "But, look, at the end of the day, luckily for me it's not life threatening. "And it's something that cost me a game of footy, enough to get subbed out of a game of footy. "So I'm in a really fortunate position. I've got the best cardiologists and doctors around me at the footy club and they've talked me through everything. "So at the moment, it's just this plan that has previously worked. "I've never had an episode when we're using this intervention and once the season ends, we'll assess if I need a procedure again." Wines and his teammates have returned to training after a mid-season bye which came with the Power languishing in 15th spot with four wins and seven losses ahead of meeting GWS in Canberra on Saturday night. Some pundits have blamed Port's fall on the coaching succession plan — head coach Ken Hinkley will step down at season's end and be replaced by long-time assistant Josh Carr. But Wines said from the February announcement of the handover "nothing has changed". "Ken's our coach, he will be for the rest of the year," he said. "And I know he's got a lot of energy and enthusiasm for the job and we'll be there for him.. "Despite not winning a premiership, I think we've always been up there and we've played a lot of finals. "Ken's done a lot for me personally as a footballer and off the field so I'm always going to play for him." AAP

Liam Wilson was agonisingly close to landing blockbuster fight on Manny Pacquiao and Tim Tszyu's undercard in Las Vegas
Liam Wilson was agonisingly close to landing blockbuster fight on Manny Pacquiao and Tim Tszyu's undercard in Las Vegas

News.com.au

time31 minutes ago

  • News.com.au

Liam Wilson was agonisingly close to landing blockbuster fight on Manny Pacquiao and Tim Tszyu's undercard in Las Vegas

Liam Wilson was agonisingly close to fighting on the same card as Tim Tszyu and Manny Pacquiao on July 19 in Las Vegas, before the deal fell through at the last minute. The Queenslander will instead fight on the same card as Liam Paro on June 25 on a non pay-per-view show in Cairns. But the 29-year-old was tantalisingly close to facing Brandon Figueroa on one of the biggest cards of the year at the MGM Grand. 'I was on it. I had a fight on that card, but it fell through and was cancelled,' Wilson tells Code Sports. 'The fight was confirmed, and then a day later it was cancelled. 'I got kinda excited about that. I always put my hand up when an opportunity arises, and that's what I did. 'I put my hand up, I'll always fight anybody, but unfortunately the fight fell through. 'I've got no idea why.' Former WBC super-bantamweight world champion Figueroa will now face Joet Gonzalez on the Pacquiao card, which also features Tszyu's rematch with Sebastian Fundora in the co-main event. That card was made official over the weekend, with Tszyu jetting to the US for a five-day media and promotional shoot whirlwind. Wilson also revealed he could barely spar, couldn't hit pads or work on the heavy bag in the lead-up to his fight of the year unanimous decision win over Youssef Dib in March. As first revealed by Code Sports, Wilson went into the fight with fractured L2 and L3 vertebrae and needed cortisone injections to get through camp. His team was close to pulling him out of the high stakes fight, and he was forced to train wearing a back brace after injuring his back seven weeks out from the fight. 'My trainer wanted me to pull out, but I just felt that if I could spar, I could fight,' Wilson told Code Sports. 'So, I fought. 'I had two fractured vertebrae in my back, so I had to manage camp and do the best I could to get through it. 'But I never thought about pulling out.' Wilson claimed a thrilling decision win, dropping Dib twice early on, before being deducted a point for a low blow in the ninth round. 'I couldn't do bag work in the lead-up, couldn't do pad work, I couldn't really even twist my body,' he said. 'Even my sparring was pretty restricted. I was just sticking to my jab and keeping my punches very light. 'I just fought with what I had and got the job done. 'Deep down, I'm just a fighter, and a little injury doesn't deter me. If there's a fight that's been put to me, I'll take it.' Three months on, Wilson is fully healed, has dropped from lightweight back to his natural super-featherweight division and is preparing to take on Ayrton Gimenez on June 25. A win will see 'Mr Damage' move within touching distance of another world title shot. Wilson was short-changed in his first world title tilt against Emanuel Navarrete in 2023, before being outgunned by Oscar Valdez last year. Wilson dropped Navarette in the fourth round, but the referee allowed the Mexican nearly half a minute to recover. Navarrete eventually stopped Wilson in the ninth, and the Aussie is hell bent on revenge. 'It's everything to me,' he says. 'I feel like I let it slip through my fingers. 'I'm not going to sit here and argue the decision. It is what it is. It's made me more hungry and it's made me the person I am today. 'It's made me realise how resilient I am. 'But that world title shot, that's the main objective. I'm holding onto the saying 'third time lucky'. 'I'm number four in the world now, and a win will move me up, and then I'm just a phone call away. 'Hopefully it's the rematch with Navarette that everyone's been wanting.'

Health Check: Stuck in biotech's ‘death zone', Opthea and Patrys check in on the sat phone
Health Check: Stuck in biotech's ‘death zone', Opthea and Patrys check in on the sat phone

News.com.au

timean hour ago

  • News.com.au

Health Check: Stuck in biotech's ‘death zone', Opthea and Patrys check in on the sat phone

Opthea and Patrys report they are still alive after failing to reach the summit, but the line's a bit crackly Renerve in Berkeley tie up for soft tissue repair Imugene furthers trial of 'off Broadway' asset With the Everest climbing season at its peak, the news from the 'death zone' is that the stricken Opthea is still alive. Can the company execute an organised descent? In a corporate update today, the eye disease drug developer said it was unable to clarify things until it had finished negotiating with its funders. So perhaps more of a non-update from camp four, although radio comms that high up can be patchy. But the company did announce that four of its eight board members would hang up their crampons. The departees are Dr Julia Haller, Dr Susan Orr, Quinton Oswald and Anshul Thakral. That leaves chairman Jeremy Levin, Kathy Connell, Lawrence Gozlan and Sujal Shah to battle on with depleted oxygen tanks. On March 24 the company reported the first of its two phase III eye disease trials failed to hit its primary endpoints. The second one fared no better and both have been abandoned in the blizzard. The studies focused on the hard-to-treat wet aged-related macular degeneration. Investors are asking how much of Opthea's residual cash of US$113 million ($176 million) will remain, if any. Under a development funding agreement (DFA), the company could be in hock to a cabal of investors for up to US$680 million. Opthea says it remains in 'active negotiations with its DFA investors … to explore possible options to deliver the best outcome for the company and its shareholders." Opthea shares were suspended on March 17 at 60 cents, for an illusory $738 million market cap. In reality, the shares potentially are worth nothing. The company promises a briefing when the DFA discussions are finalised. Stay tuned Meanwhile, Patrys' corporate update tomorrow should show whether the company has abandoned all attempts to reach the summit. Remember Patrys? The company was to launch a first-in-human phase I trial for its antibody cancer candidate, PAT-DX1. In October last year, the company said safety testing showed unacceptable margins of tolerance, so the program was canned. Patrys is forging ahead with a less favoured program, Pat-DX3 (not sure what happened with PAT-DX2). The company also intended to partner the DX-1 program. Patrys shares trade at a fraction of a cent, so are at base camp. Perhaps they can scale great heights again with the help of a decent Sherpa, er, partner. Renerve enrolls at Berkeley Nerve regeneration outfit Renerve has joined with the San Francisco based Berkeley Biologics to develop and commercialise two tissue-based products. Renerve recently started selling its FDA-cleared flagship product, the Nervalign Nerve Cuff, in the US. The company also has a nerve graft product. One initial product from the collaboration addresses the need for human dermal tissue (deeper layers of the skin often sourced from donors). The other provides amniotic tissue products, which are known for their regenerative and healing properties. 'These products have application in the medical procedures that Renerve seeks to address with its current and future Nervealign products,' Renerve says. 'Accordingly, their sale will be a natural extension of Renerve's current sales activities, using the same sales network and targeting the same surgeon and hospital customers.' The parties target the first product for a September quarter launch, with the second due on market before the year is out. Renerve will elaborate in an investor webinar scheduled for 11 am tomorrow. Imugene opens cancer site for 'off Broadway' program Immune-oncology drug developer Imugene has opened its first Australian trial site for a clinical study that hones in on a rare-ish subset of colorectal (bowel) cancer. That target is called mismatch repair-deficient/microsatellite instability high colorectal cancer, which accounts for 15% of all bowel tumours. The drug candidate is called PD1-Vaxx, which is all about inducing the body to produce polyclonal antibodies that block the PD-1 signalling pathway. This hopefully restores the immune system's ability to detect and destroy cancer cells. The trial is part of B-cell immunotherapy platform 'deprioritised' by Imugene, in favour of more show-stopping stuff such as Car-T therapies. But sometimes the off-Broadway stuff can prove the box office hit. The investigator-led phase II study is being carried out by Cancer Research UK Southampton Clinical Trials, the Royal Surrey Hospital NHS Foundation Trust and the Australasian Gastro-Intestinal Trial Group. The study's primary objective is the degree to which tumours reduce with PD1-Vaxx, pre surgery. Makes sense … Meanwhile, Imugene will seek shareholder consent to consolidate its stupendous 7.4 billion on issue, to around 200 million. Meanwhile, Inoviq (ASX:IIQ) shares this morning vaulted more than 30% after the company updated a US oncology powwow about its "breakthrough" ovarian cancer test results. As we noted already, Inoviq shares had moved already, but on 'old news' – fake news? – rather than today's 'new news'. The results were aired at the American Society of Clinical Oncology's get together in Chicago.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store